OncoCyte EBITDA 2014-2024 | OCX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OncoCyte ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OncoCyte ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$125.1B
Cencora (COR)	$45B
ICON (ICLR)	$25B
DiDi Global (DIDIY)	$19B
Avantor (AVTR)	$18.4B
Natera (NTRA)	$15.7B
Revvity (RVTY)	$15.4B
Viatris (VTRS)	$14.2B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.5B
Medpace Holdings (MEDP)	$11.2B
Charles River Laboratories (CRL)	$10.6B
Sonic Healthcare (SKHHY)	$8.8B
Doximity (DOCS)	$7.4B
Bausch + Lomb (BLCO)	$7B
HealthEquity (HQY)	$6.8B
PACS (PACS)	$6.2B
Organon (OGN)	$5.1B
Life Times (LTH)	$4.9B
Sotera Health (SHC)	$4.7B
Surgery Partners (SGRY)	$4.1B
Concentras Parent (CON)	$3B
GoodRx Holdings (GDRX)	$2.8B
BrightSpring Health Services (BTSG)	$2.5B
Ardent Health Partners (ARDT)	$2.4B
Progyny (PGNY)	$2.2B
Alignment Healthcare (ALHC)	$2.2B
Premier (PINC)	$2.1B
Ryman Healthcare (RYHTY)	$1.9B
AMN Healthcare Services Inc (AMN)	$1.8B